Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis

(University Hospitals Case Medical Center) PTC Therapeutics, Inc. today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in percent predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news